Send to

Choose Destination
See comment in PubMed Commons below
Curr Opin Investig Drugs. 2008 Apr;9(4):414-21.

Cetilistat, a new lipase inhibitor for the treatment of obesity.

Author information

University of Alberta, Clinical Pharmacology and Internal Medicine, 8440 112th Street, Edmonton, T6G 2B7, Canada.


Alizyme plc, in collaboration with Takeda Pharmaceutical Co Ltd in Japan, is developing cetilistat, an oral non-absorbed synthetic lipase inhibitor, derived from Alizyme's pancreatic lipase inhibitor research program, for the potential treatment of obesity in patients with or without diabetes. It is also under investigation for the potential management of type 2 diabetes. Several phase II clinical trials for obesity have been completed. Phase III trials were in preparation at the time of publication.

[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Loading ...
    Support Center